Study of regorafenib, toripalimab, and chemo for advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a combination of three drugs (regorafenib, toripalimab, and albumin-bound paclitaxel) as a third-line treatment for advanced pancreatic cancer that has progressed after two prior therapies. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You have advanced pancreatic cancer that cannot be removed by surgery and has spread to other parts of the body.
- Your cancer has grown after you've already tried two standard treatments.
- At least one tumor must be measurable on a scan (like a CT or MRI).
- You must be able to take care of yourself (ECOG score 0-2) and be expected to live at least 2 months.
- You must have adequate blood counts and liver/kidney function, and cannot be pregnant or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This study tests a new combination of two drugs for advanced pancreatic cancer. It aims to see if adding an immunotherapy drug (which helps your immune system attack cancer) to standard chemotherapy can help control the cancer better.
This trial tests a new medicine (IBI363) combined with chemotherapy for people with advanced pancreatic cancer that has grown after their first treatment. The goal is to see if this combination can help shrink or control the cancer longer.
This trial studies a new combination of drugs for advanced pancreatic cancer that has spread. The goal is to see if adding the study drug (chiauranib) to standard chemotherapy and immunotherapy can help control the cancer better. It is only for people who have not received prior treatment for their advanced cancer.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new Pancreatic Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.